GMED Globus Medical
- Official Name: GLOBUS MEDICAL, INC.
- Headquarters: 2560 General Armistead Ave, AUDUBON, PA, 19403 US
- CEO: Daniel Scavilla
- Website: globusmedical.com
Match Results
| Date | League | Week | Opponent | Result | Score |
|---|---|---|---|---|---|
| 2025-07-15 | 1R | Lost by 3.126 | (2.471) - 0.655 | ||
| 2025-07-17 | 1 | Won by 2.578 | 1.415 - (1.163) | ||
| 2025-07-24 | 2 | Lost by 6.839 | (2.567) - 4.272 | ||
| 2025-07-31 | 3 | Lost by 1.789 | (1.247) - 0.542 | ||
| 2025-08-07 | 4 | Won by 5.653 | 2.499 - (3.154) | ||
| 2025-08-14 | 5 | Lost by 6.474 | 9.307 - 15.781 | ||
| 2025-08-21 | 6 | Lost by 1.413 | 0.753 - 2.166 | ||
| 2025-08-28 | 7 | Won by 1.829 | 1.145 - (0.684) | ||
| 2025-09-04 | 8 | Won by 3.842 | (1.356) - (5.198) | ||
| 2025-09-11 | 9 | Lost by 4.364 | (1.150) - 3.214 | ||
| 2025-09-18 | 10 | Lost by 16.505 | (5.656) - 10.849 | ||
| 2025-09-25 | 11 | Lost by 1.844 | (2.743) - (0.899) | ||
| 2025-10-02 | 12 | Won by 3.156 | 4.523 - 1.367 | ||
| 2025-10-09 | 13 | Won by 6.574 | 2.453 - (4.121) | ||
| 2025-10-16 | 14 | Won by 1.522 | (1.784) - (3.306) | ||
| 2025-10-23 | 15 | Won by 5.992 | 7.122 - 1.130 |
Latest News

GMED or AXGN: Which Is the Better Value Stock Right Now?
GMED vs. AXGN: Which Stock Is the Better Value Option?

OPKO Health to Sell Select BioReference Assets to Labcorp for $722M
OPK's $722M BioReference asset sale to Labcorp, with a potential $150M earnout, aims to sharpen its biopharma focus and expand access to the 4Ksc...

Haemonetics Gains 149.3% in a Year: What's Driving the Rally?
HAE shares surged 149.3% in a year, fueled by strong Plasma and MedSurg growth, rising product demand and an upbeat fiscal 2027 revenue outlook.

Reasons to Add STE Stock to Your Portfolio Right Now
STERIS' strong Healthcare growth, improving AST prospects and rising Life Sciences demand bolster its outlook, despite tariff and inflationary pr...

Is it Apt to Retain Medtronic Stock in Your Portfolio Now?
MDT expands in cardiac ablation, robotics, hypertension and digital surgery, but tariff, inflation and currency risks are likely to pressure margins.

Is Spine Tech Unveiling Altering The Investment Case For Globus Medical Stock?
Globus Medical recently used the 41st Annual North American Spine Society Meeting to showcase SCRIPT, an FDA cleared patient specific spinal implant p...

BD's Revello Stent Shows Strong AGILITY Trial Results for PAD Patients
BDX's Revello stent shows strong nine-month AGILITY trial results, with high vessel patency and low failure rates, boosting its peripheral vascul...

Doximity Deepens U.S. News Alliance to Improve Patient Access to Care
DOCS extends its 13-year partnership with U.S. News, strengthening its role in physician searches, appointment booking and hospital rankings.

Is it Apt to Retain Prestige Consumer Stock in Your Portfolio Now?
PBH's brand-building, acquisitions and e-commerce growth support fiscal 2027 revenue gains, but competition and currency risks remain key challen...

Is it Apt to Retain Haemonetics Stock in Your Portfolio for Now?
HAE's MedSurg growth and NexSys PCS adoption support its prospects, but competitive pressures and unfavorable currency movements pose risks.

West Pharmaceutical Stock Gains 36.1% YTD: What's Behind the Rally?
West Pharmaceutical shares have surged 36.1% YTD, fueled by strong demand for high-value components, earnings momentum and raised guidance. Can the ra...

Is Globus Medical (GMED) Cheap On Its Spine Platform Reveal?
Globus Medical (GMED) is back in the spotlight after using the 41st Annual North American Spine Society Meeting to unveil its SCRIPT patient specific ...

What Does Globus Medical (GMED) Mean For Spine Care After Its NASS 2026 Reveal?
Globus Medical (NYSE:GMED) introduced its SCRIPT patient specific spinal implant platform at NASS 2026 following FDA clearance. The firm also presente...

Globus Medical (GMED) Stock Looks Discounted Against Its Earnings Outlook
Globus Medical has delivered a mixed share price story, with a strong multi year return sitting alongside shorter term pullbacks. This raises a simple...

Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally?
GKOS shares surge 36.8% in six months, fueled by strong sales, iDose TR and Epioxa expansion, higher guidance and promising clinical developments.

BTSG Stock Climbs 67.3% YTD: What's Driving the Rally in 2026?
BrightSpring's shares surge 67.3% year to date, fueled by strong pharmacy and provider growth, improving profitability and a brighter 2026 outloo...

Reasons to Add QuidelOrtho Stock to Your Portfolio for Now
QDEL's strong Q2 results, diversified product portfolio and cost-saving initiatives bolster its growth prospects despite persistent weakness in r...

Hims & Hers Expands Australian Women's Health Platform With Hers
HIMS expands into Australia's women's healthcare market with the Hers launch, offering personalized treatments for weight, hormonal health a...

Globus Medical to Showcase SCRIPT™ Patient-Specific Implants and New XLIF™ Prone Procedural Solution at NASS 2026
New Innovations Designed to Advance Patient-Specific Planning and Connected Surgical WorkflowsAUDUBON, Pa., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Globus M...

Here's Why You Should Retain DexCom Stock in Your Portfolio for Now
DexCom's strong margins, G7 15-day rollout and promising pipeline support its growth outlook, but factory ramp-up costs, forex and input-price pr...

ISRG Is Expanding Beyond Surgery: Here's Why the GI Opportunity Matters
Intuitive Surgical is targeting GI care with a next-generation robotic endoscope submitted to the FDA, opening a potential growth avenue beyond surger...

PacBio Teams With TychoBio to Advance AI-Driven RNA Therapeutics
PACB partners with TychoBio to harness AI and long-read RNA sequencing for rare disease therapies, aiming to improve drug efficacy and safety through ...

Here's Why You Should Add Avantor Stock to Your Portfolio for Now
AVTR's improving commercial execution, specialty product strength and raised 2026 outlook signal recovery potential despite lingering demand chal...

Veeva Systems' Basics Gains Traction With 175+ Emerging Biotech Firms
VEEV's push into early-stage biotech could unlock long-term revenue opportunities as its streamlined software solutions simplify critical drug de...

Is This the Right Time to Retain Omnicell Stock in Your Portfolio?
OMCL raises its 2026 earnings outlook on cost discipline and efficiency, but rising memory costs and delayed Titan XT adoption pose challenges.